Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy

Nanomedicine

Volumn 8, Issue 6, 2013, Pages 935-949

  Forier, Katrien ^a   Messiaen, Anne Sophie ^a   Raemdonck, Koen ^a   Deschout, Hendrik ^a   Rejman, Joanna ^a   De Baets, Frans ^b   Nelis, Hans ^a   De Smedt, Stefaan C ^a   Demeester, Joseph ^a   Coenye, Tom ^a   Braeckmans, Kevin ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

biofilm; Burkholderia cepacia complex; Burkholderia multivorans; confocal microscopy; cystic fibrosis; diffusion; nanomedicine; Pseudomonas aeruginosa; single particle tracking; sputum

Indexed keywords

MACROGOL; NANOSPHERE; POLYSTYRENE;

ARTICLE; BIOFILM; BURKHOLDERIA MULTIVORANS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; MICROSCOPY; MICROSCOPY SINGLE PARTICLE TRACKING; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM;

EID: 84878737680     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.129     Document Type: Article

References (60)

1. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol. Rev. 79(1), S23-S45 (1999).
2. Collins FS. Cystic fibrosis - molecular biology and therapeutic implications. Science 256(5058), 774-779 (1992).
3. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95(7), 1005-1015 (1998).
4. Turcios NL. Cystic fibrosis - an overview. J. Clin. Gastroenterol. 39(4), 307-317 (2005).
5. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109(5), 571-577 (2002).
6. Wallis C. Mucolytic therapy in cystic fibrosis. J. R. Soc. Med. 94(Suppl. 40), 17-24 (2001).
7. Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: beyond pseudomonas and acinetobacter. Indian J. Med. Microbiol. 29(1), 4-12 (2011).
8. Govan JRW, Hughes JE, Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J. Med. Microbiol. 45(6), 395-407 (1996).
9. Hughes J, Stewart J, Barclay G, Govan J. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect. Immun. 65(10), 4281-4287 (1997).
10. Kalish LA, Waltz DA, Dovey M et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am. J. Resp. Crit. Care Med. 173(4), 421-425 (2006).
11. Muhdi K, Edenborough FP, Gumery L et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 51(4), 374-377 (1996).
12. Frangolias DD, Mahenthiralingam E, Rae S et al. Burkholderia cepacia in cystic fibrosis - variable disease course. Am. J. Resp. Crit. Care Med. 160(5), 1572-1577 (1999).
13. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis - an emerging problem. J. Pediatr. 104(2), 206-210 (1984).
14. Dobbin CJ, Soni R, Jelihovsky T, Bye PT. Cepacia syndrome occurring following prolonged colonisation with Burkholderia cepacia. Aust. NZ J. Med. 30(2), 288-289 (2000).
15. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407(6805), 762-764 (2000).
16. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol. 9(2), 50-52 (2001).
17. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir. Res. 4(8) (2003).
18. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Resp. Care. 54(5), 628-638 (2009).
19. Savoia D, Zucca M. Clinical and environmental Burkholderia strains: biofilm production and intracellular survival. Curr. Microbiol. 54(6), 440-444 (2007).
20. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284(5418), 1318-1322 (1999).
21. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 13(1), 34-40 (2005).
22. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Resp. Crit. Care Med. 168(8), 918-951 (2003).
23. Beaulac C, Sachetelli S, Lagace J. In vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J. Antimicrob. Chemother. 41(1), 35-41 (1998).
24. Beaulac C, Sachetelli S, Lagace J. In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against Gram-negative and Gram-positive bacteria. J. Liposome Res. 9(3), 301-312 (1999).
25. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61(4), 859-868 (2008).
26. Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS ONE 4(5), e5724 (2009).
27. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39(1), 34-39 (1995).
28. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64(2), 317-325 (2009).
29. De Beer D, Stoodley P, Lewandowski Z. Liquid flow in heterogeneous biofilms. Biotechnol. Bioeng. 44(5), 636-641 (1994).
30. De Beer D, Stoodley P, Lewandowski Z. Liquid flow and mass transport in heterogeneous biofilms. Water Res. 30(11), 2761-2765 (1996).
31. Stoodley P, Boyle JD, De Beer D, Lappin- Scott HM. Evolving perspectives of biofilm structure. Biofouling 14(1), 75-90 (1999).
32. McGill SL, Cuylear C, Adolphi NL, Osinski M, Smyth H. Enhanced drug transport through alginate biofilms using magnetic nanoparticles. In: Colloidal Quantum Dots for Biomedical Applications IV. Proceedings of SPIE 7189 (2009).
33. Lai SK, O'Hanlon DE, Harrold S et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. USA 104(5), 1482-1487 (2007).
34. Bausinger R, Von Gersdorff K, Braeckmans K et al. The transport of nanosized gene carriers unraveled by live-cell imaging. Angew. Chem. Int. Edit. 45(10), 1568-1572 (2006).
35. Schoni MH. Autogenic drainage - a modern approach to physiotherapy in cystic fibrosis. J. R. Soc. Med. 82, 32-37 (1989).
36. Doring G, Conway S, Heijerman H et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16(4), 749-767 (2000).
37. Symens N, Walczak R, Demeester J, Mattaj I, De Smedt SC, Remaut K. Nuclear inclusion of nontargeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles. Mol. Pharmaceut. 8(5), 1757-1766 (2011).
38. Suh J, Choy KL, Lai SK et al. PEGylation of nanoparticles improves their cytoplasmic transport. Int. J. Nanomed. 2(4), 735-741 (2007).
39. Braeckmans K, Buyens K, Bouquet W et al. Sizing nanomatter in biological fluids by fluorescence single particle tracking. Nano. Lett. 10(11), 4435-4442 (2010).
40. Braeckmans K, Vercauteren D, Demeester J, De Smedt SC. Single particle tracking. In: Nanoscopy and Multidimensional Optical Fluorescence Microscopy. Diaspro A (Ed.). Chapman & Hall/CRC, Boca Raton, FL, USA, 1-17 (2010).
41. Savin T, Doyle PS. Static and dynamic errors in particle tracking microrheology. Biophys. J. 88(1), 623-638 (2005).
42. Deschout H, Neyts K, Braeckmans K. The influence of movement on the localization precision of sub-resolution particles in fluorescence microscopy. J. Biophotonics 5(1), 97-109 (2012).
43. Saxton MJ, Jacobson K. Single-particle tracking: applications to membrane dynamics. Annu. Rev. Biophys. Biomolec. Struct. 26, 373-399 (1997).
44. Metzler R, Klafter J. The random walk's guide to anomalous diffusion: a fractional dynamics approach. Phys. Rep. Rev. Sec. Phys. Lett. 339(1), 1-77 (2000).
45. Qian H, Sheetz MP, Elson EL. Single-particle tracking - analysis of diffusion and flow in 2-dimensional systems. Biophys. J. 60(4), 910-921 (1991).
46. Böckelmann U, Janke A, Kuhn R et al. Bacterial extracellular DNA forming a defined network-like structure. Fems. Microbiol. Lett. 262(1), 31-38 (2006).
47. Conover MS, Mishra M, Deora R. Extracellular DNA is essential for maintaining Bordetella biofilm integrity on abiotic surfaces and in the upper respiratory tract of mice. PLoS ONE 6(2), e16861 (2011).
48. Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am. J. Resp. Crit. Care Med. 162(5), 1905-1911 (2000).
49. Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol. Bioeng. 59(3), 261-272 (1998).
50. Suci PA, Mittelman MW, Yu FP, Geesey GG. Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 38(9), 2125-2133 (1994).
51. Waharte F, Steenkeste K, Briandet R, Fontaine-Aupart MP. Diffusion measurements inside biofilms by image-based fluorescence recovery after photobleaching (FRAP) analysis with a commercial confocal laser scanning microscope. Appl. Environ. Microb. 76(17), 5860-5869 (2010).
52. Zhang Z, Nadezhina E, Wilkinson KJ. Quantifying diffusion in a biofilm of Streptococcus mutans. Antimicrob. Agents Chemother. 55(3), 1075-1081 (2010).
53. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54(4), 459-476 (2002).
54. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that 'slip' through the human mucus barrier. Angew. Chem. Int. Edit. 47(50), 9726-9729 (2008).
55. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297-315 (2006).
56. Suk JS, Lai SK, Wang YY et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30(13), 2591-2597 (2009).
57. Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr. Respir. Rev. 8(1), 4-7 (2007).
58. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. 105(38), 14265-14270 (2008).
59. Guo JW, Gao XL, Su LN et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32(31), 8010-8020 (2011).
60. Kievit FM, Zhang MQ. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 23(36), H217-H247 (2011).